Navigation Links
Goodwin Biotechnology Announces a Collaboration with Spectros Corporation
Date:10/24/2011

PLANTATION, Fla. and PORTOLA VALLEY, Calif., Oct. 24, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc. (GBI) and Spectros Corporation jointly announced a collaboration for the process development and cGMP manufacturing of an antibody: dye conjugate that will be used in Phase I and Phase II clinical trials.

"The leading surgical treatment for prostate cancer is prostatectomy, or removal of the prostate," noted David Benaron, CEO at Spectros Corporation. "Unfortunately, residual tumor remains at the edge of surgery about 30% of the time, leading to a significantly higher risk of local recurrence of the cancer and higher rates of death. By collaborating with GBI on the conjugation of a fluorescent dye and a monoclonal antibody that has a high level of affinity with the prostate-specific membrane antigen, we aim to identify and minimize the residual tumor, thereby reducing the number of people who have to receive additional treatment such as high doses of radiation. This type of cancer detection, called Molecular Imaging, may represent an important advance in cancer by improving the diagnosis, individualized treatment selection and monitoring, and even survival. We look forward to clinical trials with this agent, ProstaFluor®, beginning next year."

"We're excited about the opportunity to contribute a decade of bioconjugation experience to this important project," said Muctarr Sesay, PhD, Vice President of Process Development at GBI. "The potential of this innovative approach may represent a new paradigm in the way patients are diagnosed and treated, and contribute significantly to the quality of life of those affected by this insidious disease."

About Goodwin Biotechnology, Inc.Goodwin Biotechnology is a fully integrated cGMP contract manufacturer of monoclonal antibodies, recombinant proteins and vaccines. GBI has the expertise and experience in cell line development, process development and GMP manufacturing of recombinant proteins and antibodies, as well as conjugated therapeutic proteins (e.g., antibodies conjugated to linkers for radioimmune therapy and diagnostics, other antibodies, proteins, chemotoxins, or plant toxins) by leveraging our proprietary conjugation technology. By working with GBI, our clients can enhance the value of their product candidates with clear development and manufacturing strategies and a road map to meet product requirements from the milligram, gram and kilogram range as the product candidates move along the clinical approval pathway. With nearly 20 years of experience as an independent contract manufacturer, GBI has worked with companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established biopharmaceutical companies.

About Spectros CorporationSpectros Corporation makes advanced molecular sensing and imaging devices which shed light on life-threatening diseases, including ischemia and cancer. The company's champion product, the T-Stat® broadband Tissue Oximeter, was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. Spectros also develops molecular diagnostic tools for breast and prostate cancer, including the ProstaFluor® contrast agent described herein. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.For more information, please contact:Goodwin Biotechnology:Spectros Corporation:Dave Cunningham

Ms. Elizabeth van Thillo-RohlffDirector of Business Development

Director, Marketing and SalesPhone: (954) 327-9639

Phone: 650-529-2865Email: DCunningham@GoodwinBio.com

Email: info@spectros.com
'/>"/>

SOURCE Goodwin Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
2. Goodwin Biotechnology Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
3. HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance
4. The Patent Board, IP Tracking and Analysis Firm, Ranks Heskas Science Strength in Biotechnology Industry Top 50
5. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
6. Top 450 Biotechnology (Pharmaceuticals) Report (Global)
7. STELARA® Awarded 2011 Prix Galien USA in Best Biotechnology Product Category
8. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
9. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
10. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
11. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):